UK markets closed
  • FTSE 100

    7,076.17
    +36.87 (+0.52%)
     
  • FTSE 250

    22,491.36
    +105.46 (+0.47%)
     
  • AIM

    1,251.28
    -9.76 (-0.77%)
     
  • GBP/EUR

    1.1522
    -0.0055 (-0.48%)
     
  • GBP/USD

    1.3884
    -0.0024 (-0.17%)
     
  • BTC-GBP

    41,196.03
    -563.88 (-1.35%)
     
  • CMC Crypto 200

    1,485.71
    +14.29 (+0.97%)
     
  • S&P 500

    4,179.33
    +11.74 (+0.28%)
     
  • DOW

    34,399.41
    +169.07 (+0.49%)
     
  • CRUDE OIL

    65.22
    -0.41 (-0.62%)
     
  • GOLD FUTURES

    1,814.10
    +29.80 (+1.67%)
     
  • NIKKEI 225

    29,331.37
    +518.77 (+1.80%)
     
  • HANG SENG

    28,637.46
    +219.46 (+0.77%)
     
  • DAX

    15,196.74
    +25.96 (+0.17%)
     
  • CAC 40

    6,357.09
    +17.62 (+0.28%)
     

Insights on the Non-Alcoholic Steatohepatitis (NASH) Biomarker Global Market to 2028 - by Type, Industry Verticals and Region

Research and Markets
·5-min read

Dublin, May 05, 2021 (GLOBE NEWSWIRE) -- The "Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.

According to this report, the global market for non-alcoholic steatohepatitis (NASH) biomarker is estimated to exhibit growth at a CAGR of 21.28% during the years 2021-2028.

The growing occurrence of NASH among people, paired with the increasing incidence rate of metabolic comorbidities, is boosting the reviewed market on a growth path. Besides, an increase in awareness regarding non-alcoholic fatty liver disease is opening new avenues for the NASH biomarker market over the projected period.

However, side-effects of NASH therapeutics, along with the unavailability of specialized diagnostic tests for NAFLD, are hampering the expansion of the global market on a large scale.

REGIONAL OUTLOOK

The global market includes the Asia-Pacific, North America, Latin America, Europe, and the Middle East and Africa regions.

The Asia-Pacific is expected to observe the fastest growth rate in the non-alcoholic steatohepatitis biomarker market during the forecast period. The region's growth can be attributed to the advancements in the healthcare infrastructure, the surge in the prevalence of NASH, and improvement in economic conditions. Along with this, the growing healthcare awareness in emerging economies, including India and China, is expected to further influence the growth of the NASH biomarker market around the APAC region in the upcoming years.

COMPETITIVE OUTLOOK

The prominent companies engaged in the non-alcoholic steatohepatitis (NASH) biomarker include Allergan, Merck & Co, Novartis AG, Viking Therapeutics, Bristol Myers Squibb Company, Novo Nordisk, Genfit SA, Pfizer Inc, Madrigal Pharmaceuticals, Gilead Sciences Inc, AstraZeneca, Zydus Cadila, and Siemens Healthineers.

Allergan is engaged in developing, manufacturing, marketing, and distributing specialty, biosimilar, and over-the-country products. Its product portfolio includes cenicriviroc that blocks two chemokine receptors involved in inflammatory and fibrogenic pathways. This product's phase 3 AURORA plans to enroll a large number of patients suffering from NASH. Allergen has operations in numerous regions, such as Asia-Pacific, Europe, and Latin America, serving a wide consumer base. It is headquartered in Dublin, Ireland.

Key Topics Covered:

1. Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market - Summary

2. Industry Outlook
2.1. Key Insights
2.1.1. Demand for NASH Biomarkers
2.1.2. Unmet Medical Needs
2.2. Impact of COVID-19 on Non-Alcoholic Steatohepatitis (NASH) Biomarker Market
2.3. Porter's Five Forces Analysis
2.3.1. Threat of New Entrants
2.3.2. Threat of Substitute Products
2.3.3. Bargaining Power of Buyers
2.3.4. Bargaining Power of Suppliers
2.3.5. Competitive Rivalry
2.4. Market Attractiveness Index
2.5. Vendor Landscape
2.6. Key Market Strategies
2.6.1. Contracts & Partnerships
2.6.2. Business Expansions & Divestitures
2.6.3. Acquisitions & Mergers
2.6.4. New Product Launches
2.7. Market Drivers
2.7.1. Rising Prevalence of NASH
2.7.2. Increasing Incidence Rate of Metabolic Comorbidities
2.8. Market Restraints
2.8.1. Side-Effects of NASH Therapeutics
2.8.2. Unavailability of Specialized Diagnostic Test for Non-Alcoholic Fatty Liver Disease (Nafld)
2.9. Market Opportunities
2.9.1. Growth Opportunities in Developing Regions
2.9.2. Rise in Awareness Pertaining to Non-Alcoholic Fatty Liver Disease

3. Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market - by Type
3.1. Serum Biomarker
3.2. Hepatic Fibrosis Biomarker
3.3. Apoptosis Biomarker
3.4. Oxidative Stress Biomarker
3.5. Other Types

4. Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market - by Industry Verticals
4.1. Pharma & Cro Industry
4.2. Diagnostic Lab
4.3. Academic Research Key
4.4. Hospital

5. Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market - Regional Outlook
5.1. North America
5.1.1. Market by Type
5.1.2. Market by Industry Verticals
5.1.3. Country Analysis
5.1.3.1. United States
5.1.3.2. Canada
5.2. Europe
5.2.1. Market by Type
5.2.2. Market by Industry Verticals
5.2.3. Country Analysis
5.2.3.1. Germany
5.2.3.2. France
5.2.3.3. United Kingdom
5.2.3.4. Italy
5.2.3.5. Russia
5.2.3.6. Spain
5.2.3.7. Rest of Europe
5.3. Asia-Pacific
5.3.1. Market by Type
5.3.2. Market by Industry Verticals
5.3.3. Country Analysis
5.3.3.1. China
5.3.3.2. Japan
5.3.3.3. Australia & New Zealand
5.3.3.4. India
5.3.3.5. South Korea
5.3.3.6. Asean Countries
5.3.3.7. Rest of Asia-Pacific
5.4. Latin America
5.4.1. Market by Type
5.4.2. Market by Industry Verticals
5.4.3. Country Analysis
5.4.3.1. Mexico
5.4.3.2. Brazil
5.4.3.3. Rest of Latin America
5.5. Middle East and Africa
5.5.1. Market by Type
5.5.2. Market by Industry Verticals
5.5.3. Country Analysis
5.5.3.1. Saudi Arabia
5.5.3.2. United Arab Emirates
5.5.3.3. Turkey
5.5.3.4. South Africa
5.5.3.5. Rest of Middle East & Africa

6. Competitive Landscape
6.1. Allergan
6.2. Astrazeneca
6.3. Bristol Myers Squibb Company
6.4. Genfit Sa
6.5. Gilead Sciences Inc
6.6. Madrigal Pharmaceuticals
6.7. Merck & Co
6.8. Novartis AG
6.9. Novo Nordisk
6.10. Pfizer Inc
6.11. Siemens Healthineers
6.12. Viking Therapeutics
6.13. Zydus Cadila

7. Research Methodology & Scope
7.1. Research Scope & Deliverables
7.1.1. Objectives of Study
7.1.2. Scope of Study
7.2. Sources of Data
7.2.1. Primary Data Sources
7.2.2. Secondary Data Sources
7.3. Research Methodology
7.3.1. Evaluation of Proposed Market
7.3.2. Identification of Data Sources
7.3.3. Assessment of Market Determinants
7.3.4. Data Collection
7.3.5. Data Validation & Analysis

For more information about this report visit https://www.researchandmarkets.com/r/d9bj5h

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900